[Pathogenic Autoantibodies in Myasthenia Gravis]

Area of Science:

• Neurology
• Immunology
• Autoimmune Diseases

Background:

• Myasthenia gravis (MG) is an autoimmune disorder where autoantibodies are central to its pathogenesis.
• Key autoantibodies implicated in MG include those targeting acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), and LDL receptor-related protein 4 (Lrp4).
• The pathogenicity of Lrp4 antibodies in MG remains debated due to concerns about disease specificity.

Approach:

• This review synthesizes current knowledge on autoantibody targets at the neuromuscular junction in MG.
• It evaluates the clinical significance of positivity for these autoantibodies.
• The review differentiates clinical presentation, treatment strategies, and prognosis based on specific pathogenic autoantibodies.

Key Points:

• Autoantibodies against AChR and MuSK are established as pathogenic in MG.
• The role of Lrp4 antibodies in MG pathogenesis requires further clarification due to variable disease specificity.
• Understanding specific autoantibody profiles is crucial for tailoring MG management.

Conclusions:

• Differentiating autoantibody targets is essential for understanding MG heterogeneity.
• Clinical manifestations, treatment responses, and prognoses vary significantly depending on the specific autoantibody identified.
• Further research is needed to definitively establish the pathogenic role of Lrp4 antibodies and refine diagnostic criteria for MG subtypes.